194 related articles for article (PubMed ID: 11893794)
1. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
3. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.
Bourgault C; Elstein E; Le Lorier J; Suissa S
CMAJ; 1999 Aug; 161(3):255-60. PubMed ID: 10463046
[TBL] [Abstract][Full Text] [Related]
4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
[TBL] [Abstract][Full Text] [Related]
5. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
[TBL] [Abstract][Full Text] [Related]
6. Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia.
Anis A
CMAJ; 2002 Mar; 166(6):763-4. PubMed ID: 11944763
[No Abstract] [Full Text] [Related]
7. The effects of cost-sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients.
Pilote L; Beck C; Richard H; Eisenberg MJ
CMAJ; 2002 Aug; 167(3):246-52. PubMed ID: 12186169
[TBL] [Abstract][Full Text] [Related]
8. The effect of incentive-based formularies on prescription-drug utilization and spending.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
Small RE; Freeman-Arnold SB; Goode JV; Pyles MA
Pharmacotherapy; 1997; 17(5):1011-6. PubMed ID: 9324190
[TBL] [Abstract][Full Text] [Related]
10. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.
Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB
Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126
[TBL] [Abstract][Full Text] [Related]
11. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
Liu SZ; Romeis JC
Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
[TBL] [Abstract][Full Text] [Related]
12. A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.
Wing LM; Reid CM; Ryan P; Beilin LJ; Brown MA; Jennings GL; Johnston CI; McNeil JJ; Macdonald GJ; Marley JE; Morgan TO; West MJ;
N Engl J Med; 2003 Feb; 348(7):583-92. PubMed ID: 12584366
[TBL] [Abstract][Full Text] [Related]
13. The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.
Li X; Guh D; Lacaille D; Esdaile J; Anis AH
Health Policy; 2007 Aug; 82(3):340-7. PubMed ID: 17134787
[TBL] [Abstract][Full Text] [Related]
14. Secondary prevention after acute myocardial infarction in four Canadian provinces, 1997-2000.
Pilote L; Beck CA; Karp I; Alter D; Austin P; Cox J; Humphries K; Jackevicius C; Richard H; Tu JV;
Can J Cardiol; 2004 Jan; 20(1):61-7. PubMed ID: 14968144
[TBL] [Abstract][Full Text] [Related]
15. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes.
Winkelmayer WC; Fischer MA; Schneeweiss S; Wang PS; Levin R; Avorn J
Am J Kidney Dis; 2005 Dec; 46(6):1080-7. PubMed ID: 16310574
[TBL] [Abstract][Full Text] [Related]
16. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.
Cole JA; Norman H; Weatherby LB; Walker AM
Pharmacotherapy; 2006 Aug; 26(8):1157-64. PubMed ID: 16863491
[TBL] [Abstract][Full Text] [Related]
17. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction.
Masoudi FA; Rathore SS; Wang Y; Havranek EP; Curtis JP; Foody JM; Krumholz HM
Circulation; 2004 Aug; 110(6):724-31. PubMed ID: 15289383
[TBL] [Abstract][Full Text] [Related]
18. Coverage of drug costs: reference-based pricing.
McGregor M
Can J Cardiol; 1998 May; 14(5):666-8. PubMed ID: 9627520
[TBL] [Abstract][Full Text] [Related]
19. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
[TBL] [Abstract][Full Text] [Related]
20. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
